CD72 is a co-receptor of B cells and regulates B cell activation. Although aberrant expression of CD72 has been reported in primary immune thrombocytopenia (ITP), it is uncertain whether this aberrant expression is restricted to specific B cell subsets. Furthermore, the mechanisms that regulate CD72 expression are unknown. In this study, we found higher frequency of CD19 
Summary
CD72 is a co-receptor of B cells and regulates B cell activation. Although aberrant expression of CD72 has been reported in primary immune thrombocytopenia (ITP), it is uncertain whether this aberrant expression is restricted to specific B cell subsets. Furthermore, the mechanisms that regulate CD72 expression are unknown. In this study, we found higher frequency of CD19 Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody-mediated enhanced platelet destruction and dysmegakariocytopoiesis (Cines & Blanchette, 2002; Rodeghiero et al, 2009) . B cells have been demonstrated to be involved in the pathophysiology of ITP because autoantibodies targeting platelet membrane glycoproteins (GPs), mainly GPIIb/IIIa and GPIb/IX, can be detected in a majority of ITP patients (Cines & Blanchette, 2002; Stasi, 2012) . These autoantibodies frequently result in markedly enhanced Fc receptor (FcR)-mediated phagocytosis and destruction by macrophages (Berchtold & Wenger, 1993) . In addition, regulatory B cells, which function as immune response suppressors, have been reported to be deficient in active ITP . Guo et al (2016) provided the first mechanistic explanation for the regulation of CD8 + T-cell responses by B cells. The efficacy of rituximab treatment in chronic ITP patients supports the pivotal roles of B cells in ITP (Provan et al, 2007; Zaja et al, 2010) .
B cell expansion and differentiation are regulated by the balance of signals delivered through activating and inhibitory receptors expressed on the surface of the cells. Membrane molecules, such as CD22, CD72, the Fcc receptor (FcyR)IIb and PD-1 (also termed PDCD1) negatively regulate B cell receptor (BCR) signalling and prevent overstimulation of the B cells, whereas BCR signalling is up-regulated by membrane molecules such as CD19 (Dal Porto et al, 2004; Tsubata, 2012) . Recent studies demonstrated that several of these coreceptors, including CD72, FccRIIb and CD5 have been directly linked to ITP (Iyori et al, 1995; Xu et al, 2008 Xu et al, , 2010 Liu et al, 2011; Zhou et al, 2012) .
CD72 is a 45 kDa type II transmembrane protein that belongs to the C-type lectin family, which is expressed in all stages of B-cell development except plasma cells (Li et al, 2008) . Human CD72 is preferentially expressed on naive mature B cells (Yamazaki et al, 2005) and contains immunoreceptor tyrosine-based inhibition motifs (ITIMs) and ITIM-like sequence in the cytoplasm. CD72 plays a negative role in regulating BCR-induced signalling in primary mature B cells (Li et al, 2006) , but it may also transmit a positive signal independent of the BCR (Wu et al, 2001) . CD72 engages by interacting with its ligand CD100 (also termed SEMA4D) can induce tyrosine dephosphorylation of CD72 and dissociation of SHP1 from CD72 (Kumanogoh et al, 2000) . Consequently, CD72 ligation can drive B cells into cell cycle and induce proliferation of activated B cells.
Abnormal expression and function of CD72 on B cells have been reported in some autoimmune diseases. In patients with lupus nephritis, downregulation of CD72 was related to class switching on B cells, suggesting that CD72 is a useful marker for determining class switching of B cells (Nakano et al, 2007) . A significantly increased expression of CD72 on B cells was found in primary Sj€ ogren syndrome (pSS) patients (Jamin et al, 1993; Smith et al, 2004) . The CD72 mean fluorescence intensity (MFI) was impressively higher on CD5 + than CD5 À B cells in peripheral blood and synovial fluid of rheumatoid arthritis (RA) patients (Jamin et al, 1993) . Our group observed aberrant levels of CD72 mRNA in ITP patients, indicating that CD72 might be involved in the pathogenesis of ITP (Zhou et al, 2012 (Potter et al, 2002) . A recent study revealed that the frequency of CD19 + B cells was increased in active ITP patients compared with healthy controls (Zhu et al, 2014) . The spleen was found to be indispensable for the maintenance of peripheral memory B-cell homeostasis in ITP, reflected by the reduction of total CD27 + memory B cells in post-splenectomised ITP patients (Martinez-Gamboa et al, 2009 ). These findings indicate that there might be changes in the distribution of B cell subsets in ITP patients. To date, distinct abnormalities of B cells have not been elucidated in ITP patients, and little is known about abnormalities regarding CD72 expression on B cell subsets.
In the present study, we investigated for the first time the homeostasis of peripheral blood B cells in ITP patients and the status of CD72 on different B cell subsets. We also looked into the mechanisms that regulate B cell-associated CD72 expression.
Materials and methods

Patients and controls
Fifty active ITP patients with a platelet count <50 9 10 9 /l who had not been treated with glucorticosteroids for at least 1 month or never treated with rituximab before sampling (27 females, 23 males; age range 19-62 years, median 37Á5 years; platelet count range 1-35 9 10 9 /l, median 25 9 10 9 /l) were enrolled at our hospital between September 2014 and October 2015. All of the cases met the diagnostic criteria of chronic ITP as previously described (Rodeghiero et al, 2009) . Twenty ITP patients in remission with normal platelet counts (11 females, 9 males; age range 27-72 years, median 38Á5 years; platelet count range 122Á4-201Á3 9 10 9 /l, median 156Á2 9 10 9 /l) and 51 healthy controls, matched for sex and age with the study population were also enrolled. Twenty-nine active ITP patients had evaluation of platelet antibodies (18 females and 11 males; age range 19-62 years, median 49Á5 years; platelet count range 1-35 9 10 9 /l, median 18Á5 9 10 9 /l). The study was approved by the Institutional Review Board and written informed consent was obtained from each study subject.
Preparation of plasma and cells
Fresh venous blood samples were collected using ethylenediaminetetraacetic acid (EDTA) as an anticoagulant, then centrifuged for 10 min at 800 rpm. Plasma was separated and then stored at 80°C until used. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation at 2000 rpm for 20 min at 20°C using FicollHypaque. PBMCs re-suspended in phosphate-buffered saline (PBS) were incubated with optimal amounts of phycoerythrin (PE) conjugated anti-human CD19 (BD Biosciences, San Diego, CA, USA) and cell sorting was carried out on a BD FACSAria cell sorter. The populations thus obtained were >95% purity.
Cell culture and stimulation
Freshly isolated PBMCs were cultured in 96-well flat bottomed plates at 1 9 10 6 cells/well in complete RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) and incubated in humidified air in 5% CO 2 at 37°C. To investigate the effect of the following reagents on CD72 expression, we incubated PBMCs with recombinant human CD40 ligand (CD40L) (Biolegend, San Diego, CA, USA) at different concentrations (0, 0Á5, 1 and 1Á5 lg/ml), 2Á5 lg/ml CpG (InvivoGen, San Diego, CA, USA), 5 lg/ml anti-IgM/IgG/IgA (Jackson ImmunoResearch, West Grove, PA, USA). Isolated CD19 + cells were cultured with the following human recombinant cytokines at 1-1Á5 9 10 5 cells/well to evaluate their effect on CD72 expression: 50 ng/ml interleukin (IL) 10, 50 ng/ml IL21, 50 ng/ml IL4 (all from Peprotech, Rocky Hill, NJ, USA), 20 ng/ml B-cell activating factor (BAFF, also termed TNFSF13B) (R&D Systems, Minneapolis, MN, USA).
Flow cytometric analysis
For analysis of the distribution of major B-cell subpopulations and the expression of cell surface markers, PBMCs and cells collected from cell culture were incubated with allophycocyanin (APC) conjugated anti-human CD27 (Biolegend), PE conjugated anti-human CD19 (BD Biosciences), fluorescein isothiocyanate (FITC) conjugated anti-human CD72 
Enzyme-linked immunosorbent assay (ELISA)
Plasma soluble CD40L (sCD40L) was measured in duplicate by ELISA kit according to the manufacturer's instructions (Neobioscience Technology, Shenzhen, China). The lower limit of detection was 30 pg/ml for sCD40L.
RNA isolation and real-time polymerase chain reaction (RT-PCR) analysis
Total RNA was isolated by Trizol reagent (Invitrogen, Carlsbad, CA, USA), and converted to cDNA using a reverse-transcription system (TransGen Biotech, Beijing, China).
Quantitative PCR was performed using SYBR Green (Applied Biosystems, Foster City, CA, USA) as a double-strand DNAspecific binding dye on an ABI-7500 Sequence Detection System (Applied Biosystems). The sequences of the amplification primers were as follows:
Gene expression was normalized to ACTB mRNA levels used as an internal control in each sample by 2 ÀMMCt method. All experiments were conducted in triplicate.
Evaluation of anti-platelet antibodies
Whole blood samples were collected in EDTA, kept refrigerated at 4°C and tested within 7 days of collection. Eluate preparation was performed with the GTI Pak Auto kit according to the manufacturers' instructions (GTI Diagnostics, Brookfield, WI, USA). Acid eluates, prepared by elution at pH 3Á0 from patient platelets were added to microwell strips containing three different immobilized glycoprotein complexes -GPIIb/IIIa, GPIb/IX and GPIa/IIa. Antibody bound to the immobilized GPs was detected via a standard ELISA.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). All values were expressed as median and range. Differences between groups were compared using the two-tailed nonparametric MannWhitney U test or Kruskal-Wallis test. Changes in CD72 expression and frequency of B cell subsets after CD40L stimulation were compared using Wilcoxon signed rank test. Correlation was examined using Spearman rank correlation analysis. P < 0Á05 was considered statistically significant. 3Á2-10Á2%) compared with patients in remission (median: 4Á3%, range: 2Á1-9Á0%, P = 0Á0053) and healthy controls (median: 4Á9%, range: 2Á5-7Á5%, P = 0Á043) (Fig 1B) . A significant increase in the frequency of B cells expressing CD27 was observed in active ITP patients (median: 45Á4%, range: 20Á2-78Á1%) compared with patients in remission (median: 28Á2%, range: 9Á4-53Á3%, P < 0Á0001) and healthy controls (median: 33Á0%, range: 17Á4-69Á4%, P = 0Á0002) ( Fig 1C) .
Results
B-cell subset alterations in ITP patients
Corresponding to the increase of memory B cells, the frequency of CD27 À B cells was significantly reduced in patients with active ITP (median: 54Á5%, range: 21Á1-71Á3%) compared with remission patients (median: 71Á8%, range: 44Á0-90Á2%, P < 0Á0001) and healthy controls (median: 66Á9%, range: 25Á3-82Á1%, P = 0Á0002) (Fig 1D) . No significant difference in CD19 + CD27 high B cells was detected among the various groups (ITP, median: 1Á8%, range: 0Á8-8Á5%; ITP in remission, median: 1Á3%, range: 0Á4-2Á7%; controls, median: 1Á2%, range: 0Á5-5Á3%, P = 0Á1553, Fig 1E) . Altogether, these results suggested that ITP patients exhibited disturbed B cell subset distribution in their peripheral blood.
Expression of CD72 on CD19 + CD27 + B cells was increased in ITP patients
Given that CD72 expression on plasma cells is rare, we investigated the expression of this molecule on naive and memory B cells. The frequency of CD72 on CD19 + B cells and CD19 + CD27 + cells was significantly higher in active ITP patients (median: 84Á8%, range: 70.4-98Á9% and median: 67Á8%, range: 51Á1-88Á5%, respectively) compared with patients in remission (median: 80Á9%, range: 66Á9-89Á3%, P = 0Á0219 and median: 51Á2%, range: 35Á5-69Á5%, P < 0Á0001, respectively) and healthy controls (median: 75Á4%, range: 62Á7-88Á5%, P < 0Á0001 and median: 52Á8%, range: 26Á3-68Á7%, P < 0Á0001, respectively) ( Fig 2B) . M. Lyu et al 419-1609, P = 0Á0200) and healthy controls (median: 1031, range: 488-1560, P = 0Á0150) (Fig 2C) . However, no significant differences were found in the frequency of CD72 on CD19 + CD27 À cells among the three groups (ITP, median: 98Á1%, range: 91Á8-98Á8%; ITP in remission, median: 97Á7%, range: 91Á7-98Á9%; controls, median: 97Á3%, range: 90Á1-98Á9%, P = 0Á1153, Fig 2B) . The apparent increase in the MFI of CD72 on CD27 À B cells did not reflect an absolute increase in this subset, as the percentage of CD27 À B cells in active patients was actually decreased compared to patients in remission and healthy controls.
Correlations between CD72 expression and clinical characteristics in ITP patients
We examined the correlations between CD72 expression on various B-cell subsets and clinical manifestations. The CD72 MFI on CD19 + CD27 + cells was higher in active ITP patients with platelet count <25 9 10 9 /l compared to patients with platelet count ≥25 9 10 9 /l (P = 0Á004, Fig 3B) . However, no significant difference of CD72 MFI on CD19 + B cells and CD19 + CD27 À cells was found between the two platelet count groups (P > 0Á05, Fig 3B) . Similarly, there was no significant difference in the frequency of CD72 on all B cell subsets between the two platelet count groups (P > 0Á05, Fig 3A) . Anti-platelet antibodies were positive in 14 patients, of which 9 (64Á3%) were GPIIb⁄IIIa, 1 (7Á1%) was GPIb/IX, 2 (14Á3%) had autoantibodies against both GPIIb⁄IIIa and GPIb/IX and 2 (14Á3%) had autoantibodies against both GPIIb/IIIa and GPIa/IIa. The CD72 MFI on CD27 + B cells was much higher in autoantibody-positive patients than that in autoantibodynegative patients (P = 0Á0148, Fig 3D) . No significant difference in CD72 MFI on CD19 + B cells and CD19 + CD27 À cells was found between autoantibodies groups (P > 0Á05, Fig 3D) . We also did not observe a significant difference in the frequency of CD72 on all B cell subsets between autoantibody groups (P > 0Á05, Fig 3C) . There was no correlation between CD72 expression on B cell subsets with sex or age in active ITP patients (data not shown).
CD40L is important for the upregulation of CD72 on CD19 + CD27 + cells
Pivotal signals for B cell activation include engagement of BCR, ligation of CD40 and stimulation of innate immune signals, such as toll-like receptors (TLRs). To investigate a potential regulation of CD72, we analysed the expression of this molecule on CD19 + CD27 + cell from healthy controls after co-culture of B cells with CD40L, CpG and anti-immunoglobulin (Ig). As can be seen in Fig 4A, CD40L significantly raised the frequency of CD72 on CD19 + CD27 + B cells (median: 65Á3%, range: 54Á7-93Á3% vs. median: 44Á7%, range: 30Á1-66Á3%, P < 0Á0001). In contrast, CpG and antiIg stimulation did not induce the upregulation of CD72 in ITP (CpG, median: 45Á3%, range: 30Á2-77Á0%, P = 0Á202; anti-Ig, median: 44Á0%, range: 37Á6-80Á9%, P = 0Á360, Fig 4A) . To determine whether the increased CD72 expression on CD19 + CD27 + B cells could be explained by CD40L, we incubated PBMCs from controls with a gradual increase of either CD40L concentration or incubation time. CD72 expression was obviously increased when incubated with CD40L at concentrations of 0Á5 lg/ml or more (0 lg/ml, median: 47Á50%, range: 37Á8-57Á3%; 0Á5 lg/ml, median: 65Á5%, range: 54Á3-75Á4%, P < 0Á0001; 1 lg/ml, median: 70Á0%, range: 57Á9-80Á7%, P < 0Á0001; 1Á5 lg/ml, median: 72Á1%, range: 56Á5-80Á8%, P < 0Á0001, Fig 4B) . Notably, there was no significant difference in the frequency of CD72 on CD27 + B cells stimulated by CD40L alone at concentrations of 1 and 1Á5 lg/ml. Furthermore, CD72 expression following incubation with 1 lg/ml CD40L was 29Á0% increased at 24 h (median: 53Á8%, range: 42Á1-64Á9% vs. median: 41Á7%, range: 30Á4-46Á9%, P < 0Á0001), 58Á3% increased at 48 h (median: 66Á0%, range: 49Á4-84Á5%, P < 0Á0001) and 44Á1% increased at 72 h (median: 60Á1%, range: 42Á7-85Á7%, P < 0Á0001) (Fig 4C) . After 72 h of incubation, the frequency of CD72 on CD27 + B cell was lower than that after 48 h of incubation (P = 0Á0097).
CD72 expression on CD19 + CD27 + cell was enhanced by IL10 and BAFF, but reversed by IL21 combined with CD40L
Given that recent research considered IL4, IL10, IL21 and BAFF to be involved in B cell activation of ITP patients (Ettinger et al, 2005; Zhu et al, 2009; Vazquez et al, 2015) , we sought to determine whether specific cytokines could work in concert with CD40L to modulate CD72 expression on CD27 + B cells. When used in combination with CD40L, IL21 reduced the increased expression of CD72 on CD19 + CD27 + B cells (median: 59Á5%, range: 49Á3-67Á5% vs.
median: 65Á7%, range: 60Á0-78Á3%, P = 0Á0066), whereas IL10 and BAFF further induced CD72 upregulation (median: 75Á7%, range: 59Á7-91Á0%, P = 0Á0005 and median: 74Á6%, range: 66Á0-88Á9%, P = 0Á0001, respectively) (Fig 5) . However, IL4 had no effect on CD72 expression on CD19 + CD27 B cells following CD40L stimulation (median: 64Á8%, range: 53Á5-72Á9%, P > 0Á05, Fig 5) .
The effect of CD40L on CD72 MFI, CD72 mRNA levels and the frequency of B cell subsets in ITP patients
As was demonstrated in our previous study, CD40L had the ability to regulate frequency of CD72 on CD19 + CD27 + cells.
We therefore analysed the MFI levels of CD72 on all B cell subsets in active ITP patients after co-culture of PBMCs with CD40L. Only CD72 MFI on CD27 + B cells, but not CD27 À B cells, was significantly increased in ITP patients (P = 0Á008), while CD40L significantly raised CD72 MFI levels of all B cell subsets in healthy controls (P < 0Á05) (Fig 6A-C) . Total CD72 mRNA levels in PBMCs were significantly increased after stimulation with CD40L in active ITP patients (P = 0Á007) and controls (P = 0Á013) (Fig 6D) . Although the frequency of CD27 + memory B cells had a trend to increase after CD40L stimulation in ITP patients and controls, no statistical difference was found (P > 0Á05, Fig 6E) . Similarly, there was no significant change in the frequency of CD27 À naive B cells after CD40L stimulation in ITP patients or in healthy controls (P > 0Á05, Fig 6F) .
Correlations between CD72 on CD19 + CD27 + B cells and CD40L on T cells in ITP
Given that our results demonstrated that CD40L mediated CD72 upregulation on CD19 + CD27 + B cells from ITP patients in vitro, we next sought to understand the role of CD40L expressed on CD4 + cells and sCD40L on CD72
upregulation. CD40L expression on T cells and sCD40L levels were shown to be significantly higher in ITP patients (median: 5Á2%, range: 2Á2-17Á2% and median: 234Á9 pg/ml, range: 53Á0-1904Á0 pg/ml, respectively) compared with patients in remission (median: 4Á2%, range: 1Á2-8Á7%, P = 0Á045 and median: 121Á7 pg/ml, range: 40Á75-341Á3 pg/ ml, P = 0Á042, respectively) and healthy controls (median: 3Á5%, range: 1Á1-10Á1%, P = 0Á022 and median: 118Á2 pg/ml, range: 46Á83-479Á4 pg/ml, P = 0Á015, respectively) (Fig 7A-B) . Furthermore, we found a significant correlation between CD40L expression on T cells and the MFI levels of CD72 on CD19 + CD27 + B cells in ITP patients (r = 0Á451, P = 0Á0348, Fig 7C) . These data provided indirect evidence that the high levels of CD40L on CD4 + cells in ITP patients might contribute to the increased levels of CD72 on CD19 + CD27 + B cells.
Discussion
Alterations in the frequency and activation status of specific subsets of circulating B cells have been observed in various autoimmune diseases and are associated with disease duration, disease activity and production of disease-specific autoantibodies (Potter et al, 2002; Martinez-Gamboa et al, 2009) . In this study, our findings showed ITP patients had increased frequency of circulating CD27 + memory B cells and reduced frequency of CD27 -naive B cells. For CD27 + memory B cells, apart from the rapid differentiation into plasma cells with antigen-dependent and independent stimulation, other B cell functions, possibly antigen presentation or cytokine production, which contribute to amplification of autoimmunity (Dorner, 2006) . The repletion of B cells after anti-CD20 therapy is characterized by modulation of B cell CD72 mean fluorescence intensity (MFI) on B cell subsets were compared between patients with a platelet count <25 9 10 9 /l (n = 14) and those with a platelet count ≥25 9 10 9 /l (n = 14). (C) The frequency of CD72 and (D) CD72 MFI on B cell subsets were compared between autoantibody-positive patients (n = 14) and autoantibody-negative patients (n = 15). The line indicates the median. *P < 0Á05, **P < 0Á01. subset composition, with a preferential recurrence of naive B cells and a delay in the recurrence of memory B cells (Roll et al, 2006) . Therefore, the increased proportion of memory B cells might be a key element in the pathogenesis of ITP and provides a reliable marker of disease activity. Many co-receptors, such as CD72, FccRIIb and others, have been shown to negatively regulate B cells, thus maintaining self-tolerance (Dal Porto et al, 2004) . However, in some studies, CD72 was reported to be a positive regulator intensely triggered by the over-expression of CD100 on activated CD4 + T cells (Kumanogoh et al, 2000) . Recognizing the importance of the regulatory molecule CD72 in autoimmunity, several studies previously reported the aberrant expression of CD72 on B cells in systemic lupus erythematosus (Nakano et al, 2007) , RA (Jamin et al, 1993) and pSS (Smith et al, 2004) . Our data showed that CD72 expression on B cells seemed to be higher in active ITP patients. Specifically, this upregulation of CD72 was not present on all B subsets and it was primarily restricted to the CD27 + memory B cell population. CD27 À B cells showed normal or slightly + cells were measured in the presence of CD40L at different concentration (0, 0Á5, 1 and 1Á5 lg/ml) for 48 h in healthy controls (n = 11). (C) Contour plots and percentages of CD72 among CD19 + CD27 + cells were measured in the presence of 1 lg/ml CD40L for different times (0, 24, 48 and 72 h) in healthy controls (n = 9). The line indicates the median. *P < 0Á05, **P < 0Á01, ***P < 0Á001.
Fig 5.
Following stimulation of CD40L at concentration of 1 lg/ml for 48 h, CD72 expression on CD19 + CD27 + cells was regulated by IL10, BAFF, IL21 and IL4 in healthy controls (n = 9). The line indicates the median. *P < 0Á05, ***P < 0Á001. increased expression of CD72. Despite the fact that CD100 expression was reported not to be increased in ITP patients (Zhou et al, 2012) , CD72 dysregulation on CD27 + memory cells was strongly correlated with anti-platelet antibodies and platelet count. These observations suggested that the increased expression of CD72 on the CD27 + memory B subset is associated with ITP disease activity and autoantibody production. B cells are in an abnormal state of activation in autoimmune diseases (Smith et al, 2004; Nakano et al, 2007) . It has been reported that three signals are required for optimal activation of B cells: antigen binding to the BCR, specific binding of CD40L expressed by activated T cells with CD40 expressed by B cells, and engagement of a TLR (Ruprecht & Lanzavecchia, 2006) . Our data showed that CD40L stimulation alone caused significant upregulation of CD72 expression on CD27 + B cells from healthy donors, whereas TLR stimulation or BCR crosslinking alone had no effect on levels of CD72. Further, we found that incubation with higher concentrations of CD40L (>0Á5 lg/ml) for 48 h significantly upregulated CD72 expression on CD27 + B cells but this was not maintained following long-term incubation with CD40L. We postulated that long-term exposure to CD40L resulted in a decrease from peak expression of CD72 because of differentiation of activated B cells into plasma cells. Abnormal B cell-associated cytokines have been shown to be involved in the pathogenesis of ITP. Zhou et al (2009)-found elevated serum BAFF levels in patients with ITP, which promoted the survival of CD19 + and CD8 + cells, and increased the apoptosis of platelets and the secretion of cinterferon (Zhu et al, 2009) . IL21 has profound effects on B cells by promoting plasma cell differentiation from CD27 + memory B cells (Ettinger et al, 2005) . Elevated IL21 was found in ITP patients and was positively correlated to Th17 cells and Th1 cells (Zhu et al, 2010) . Levels of IL10 and IL4, which are known to help B cells produce antibodies Vazquez et al, 2015) , were significantly higher in ITP patients compared to controls (Ma et al, 2014) . In the present study, we observed that, following CD40L stimulation, the expression of CD72 on CD27 + memory cells was tightly regulated by these cytokines. In combination with CD40L, IL10 and BAFF further enhanced the expression of CD72 on CD19 + CD27 + B cells, whereas IL21 reduced CD72 up-regulation. IL4 had no effect on CD72 expression on CD27 + memory B cells. Altogether, apart from CD40L, B cell-associated cytokines might be other regulators of CD72 expression on CD19 + CD27 + cells in ITP patients.
Total B cells and CD19 + CD27 + memory B cells from both healthy controls and ITP patients exhibited enhanced MFI levels of CD72 following incubation with CD40L. Interestingly, there was no significant difference in CD72 MFI on CD19 + CD27 À B cells from ITP patients after CD40L stimulation. In contrast, CD72 MFI on CD19 + CD27 À B cells from controls was increased. These findings suggested that CD40L exerted upregulation roles exclusively for CD72 on CD27 + B cells in ITP. CD40L also increased the total levels of CD72 mRNA in both ITP patients and healthy controls, indicating that the increased CD72 levels resulted from CD72 mRNA upregulation. In addition, we observed no significant alteration of the B cell subsets in ITP patients and controls after CD40L stimulation. Given that higher levels of CD72 were not associated with the expansion of memory B cells, we postulated that the increased CD72 levels detected on memory B cells could be a result of B cell activation by CD40-CD40L interaction in ITP. CD40 interacts with CD40L expressed on T cells and provides a major growth signal to B cells. CD40-CD40L interaction plays an important role in the pathology of ITP (Nagahama et al, 2002; Meabed et al, 2007) . Similar to previous reports (Nagahama et al, 2002; Meabed et al, 2007) , we observed that CD40L expression on CD4 + T cells and sCD40L in plasma were increased in active ITP patients compared to patients in remission and healthy controls. Importantly, a significant positive correlation was found between CD40L expression on CD4 + T cells and the MFI levels of CD72 on CD27 
